Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of ITI-333 in Healthy Subjects
NCT05732194Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ITI-333 (4 cohorts), sponsored by Intra-Cellular Therapies. Primary endpoints: Area Under the Curve from Time Zero to the End of the Dosing Interval at Day 14, Maximum Observed Plasma Concentration at Day 14 and 7 more. Started Jan 2023; status: completed.
02
Drugs
ITI-333
Beyond the preview
Go deeper on NCT05732194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732194.